In summary, by employing PDX models that retain the natural heterogeneity of lung cancer and represent the two most prevalent EGFR mutations, we validated the cooperative interactions between TKIs and mAbs, as well as demonstrated that this treatment scenario is able to durably control tumors expressing mutant forms of EGFR. The gene discussed is EGFR; the disease is lung carcinoma.